Keep responsibility connected to the decision.
A medicines opportunity can cross pharmacy, finance, procurement and clinical governance before anyone can act. The difficult part is often the relationship between those responsibilities: who can interpret the evidence, who can authorise the change and who will notice if implementation creates a new problem. PHARMORIS development asks how a clearer record of that journey could help the people already responsible for it.
The current programme is controlled development, with no claim of a production clinical service or a point-of-prescribing capability. Any proposed evaluation needs an intended-use and applicability assessment for its actual setting. This page is an invitation to define that assessment together, rather than a declaration that local or national assurance has been completed.
Map authority before mapping the workflow
A senior medicines lead may sponsor an opportunity without holding every approval it requires. A community pharmacy owner may control investment while a pharmacist holds professional responsibility for a service. We would begin by identifying those distinctions. The proposed governance artefact is a responsibility and escalation map for one workflow: the sponsor, reviewer, decision owner, implementation owner and route for unresolved concerns. A named role should correspond to real authority in the organisation.
Separate a signal from permission to act
Information can make a question worth investigating without making a change appropriate. A possible value signal should therefore remain separate from the decision that follows it. Reviewers need to understand the source, local assumptions and missing evidence before authorising further work. A proposed evaluation would examine whether the record preserves a rejected or deferred opportunity as clearly as an accepted one, including the reason and the conditions under which it could be reconsidered.
Make disagreement useful
A clinical reviewer may see a risk that a financial model does not capture. An operational lead may identify a staffing constraint that changes a seemingly attractive proposal. The proposed workflow should give those observations a visible place and a route to resolution. We would test whether reviewers can request further material, change the scope or pause the work without losing the original question. Completion rates alone would be a poor measure if they reward closing cases that should remain open.
Illustrative stock photography of a person in scrubs using a clipboard. It does not show a NEUVIOR employee, customer, clinical service, professional assessment or patient record.
YuriArcursPeopleimages · Focused Medical Professional Reviews Chart in Hospital SettingEnvato Elements commercial licence
Source and image notes
Full frame retained; EXIF orientation honoured, proportionally resized and encoded as WebP. No crop, creative colour grading, compositing or generative changes.
Clinical and service reviewers
Where does information become somebody’s responsibility to act?
An evidence summary can inform a discussion without authorising the next clinical or service action. Walk through the handover between source, reviewer, decision owner and receiving team. The pause point asks what happens when authority or scope remains unresolved, keeping proposed governance questions separate from a claim of completed PHARMORIS assurance.
Editorial decision model, not measured NEUVIOR results.
Keep judgement attached to the authorised person
This lens follows the information that a qualified person would consider and the scope of their authority. The purpose of proposed assistance is examinable support, rather than transferring a clinical duty to a summary, interface or mandatory approval click.
Name the authorised reviewer and conditions for disagreement.
Source context
A signal should retain the material, date and scope that make it interpretable. Conflicting or missing information needs a visible response before the workflow moves on. A source-linked summary can support review; it does not inherit the professional authority required for a consequential clinical decision.
- Interpret
Permitted source, intended task and unresolved information.
A useful next stepWhat does this information actually support?
A source, professional judgement, authorised decision and accepted handover require distinct, visible responsibilities.
Evaluate the handover as well as the meeting
An approved decision is only part of the operating story. Someone must understand the change, accept responsibility for the next step and know when to return an exception. For an evaluation, we would propose examining whether the decision rationale reaches that person intact. Useful measures could include unresolved ownership questions, missing information at handover and the effort required to reconstruct why a task exists. These are proposed process measures, not evidence of improved patient outcomes.
Keep supplier and adopter responsibilities explicit
NHS clinical-safety standards distinguish the manufacture of health IT from its deployment and use. Their applicability should be assessed for the particular product and setting. A joint discussion should therefore identify which evidence NEUVIOR would need to supply and which local decisions remain with the adopting organisation. The proposed responsibility map would record those boundaries, the documents needed and the accountable reviewers. A supplier's internal check cannot stand in for an organisation's own deployment decision.
Decide what should stop the evaluation
Before activity begins, the parties should agree the consequences of unresolved authority, unavailable source permissions or a workflow that moves beyond its assessed intended use. A useful pause is a decision, not a project failure to hide. The evaluation could continue within a narrower scope, seek further specialist assessment or stop. Any future medical-purpose functionality would need its own regulatory consideration; broad marketing language should not make that determination on the user's behalf.
Bring the people who own the difficult boundary
A productive next discussion brings a medicines lead together with the relevant clinical, operational and assurance colleagues. Nominate one recurring decision and the record you currently use to manage it. We can then consider whether a bounded, non-clinical evaluation would produce useful evidence about ownership, review quality and handover, with any further work and responsibilities agreed separately.
Primary guidance for the conversation
NHS clinical-safety applicability guidance provides the starting point for assessing DCB0129 and DCB0160. The 2026 national standards review describes the review context. MHRA software guidance informs medical-device qualification questions. These references are not evidence of PHARMORIS certification, approval or deployment.
